Alpha 2.0
Login Register
» Articles » PMID: 23884041

Responsiveness to Reduced Dosage of Rituximab in Chinese Patients with Neuromyelitis Optica

Overview
Journal Neurology
Specialty Neurology
Date 2013 Jul 26
PMID 23884041
Citations 59
Authors
Chun-Sheng Yang
Li Yang
Ting Li
Da-Qi Zhang
Wei-Na Jin
Min-Shu Li
Ning Su
Nannan Zhangning
Qiang Liu
Zong-Hong Shao
Chunshui Yu
Fu-Dong Shi
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the effect of a lower dose of rituximab in depleting B lymphocytes, maintaining low B-cell counts, and relapse in patients with neuromyelitis optica (NMO) and NMO spectrum disorders.

Methods: We treated 5 Chinese patients with deteriorating NMO and NMO spectrum disorders with a 100-mg IV infusion of rituximab once a week for 3 consecutive weeks, followed by additional infusion of the same dosage depending on circulating B-cell repopulation.

Results: This reduced dosage of rituximab was sufficient to deplete B cells and maintain low B-cell counts. None of the treated patients experienced relapse, and all patients exhibited stabilized or improved neurologic function during the 1-year follow-up period. MRI revealed the absence of new lesions, no enhancement in spinal cord and brain, a significant shrinkage of spinal cord segments, and a reduction/disappearance of previous brain lesions.

Conclusion: A lower dosage of rituximab may be sufficient in depleting B cells, maintaining low B-cell counts, and preventing disease progression in Chinese patients with NMO.

Citing Articles

Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.

Qi Y, Liu R, Zhao Y, Zhang L, Zhang Q, Li L Neurol Sci. 2025; .

PMID: 39951176 DOI: 10.1007/s10072-025-08046-5.

Efficacy and safety of combined low-dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy.

Du Y, Yan Q, Li C, Zhu W, Zhao C, Hao Y Ann Clin Transl Neurol. 2024; 12(1):180-191.

PMID: 39660535 PMC: 11752089. DOI: 10.1002/acn3.52270.

CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

Zhang W, Han Y, Huang H, Su Y, Ren H, Qi C J Neuroinflammation. 2024; 21(1):313.

PMID: 39616380 PMC: 11607829. DOI: 10.1186/s12974-024-03305-2.

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

Komlodi-Pasztor E, Escarra-Senmarti M, Bazer D, Bhatnagar A, Perez Heydrich C, Messmer M Front Immunol. 2024; 15:1433442.

PMID: 39295862 PMC: 11408186. DOI: 10.3389/fimmu.2024.1433442.

B-cell depletion limits HTLV-1-infected T-cell expansion and ameliorate HTLV-1-associated myelopathy.

Lv A, Fang Y, Lin X, Chen J, Song H, Wang N Ann Clin Transl Neurol. 2024; 11(10):2756-2768.

PMID: 39186315 PMC: 11514899. DOI: 10.1002/acn3.52190.

References
1.
Jacob A, Weinshenker B, Violich I, McLinskey N, Krupp L, Fox R . Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65(11):1443-8. DOI: 10.1001/archneur.65.11.noc80069. View
2.
Bedi G, Brown A, Delgado S, Usmani N, Lam B, Sheremata W . Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011; 17(10):1225-30. DOI: 10.1177/1352458511404586. View
3.
Tan C, Koralnik I . Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010; 9(4):425-37. PMC: 2880524. DOI: 10.1016/S1474-4422(10)70040-5. View
4.
Blum S, Gillis D, Brown H, Boyle R, Henderson R, Heyworth-Smith D . Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2010; 82(6):659-63. DOI: 10.1136/jnnp.2010.220475. View
5.
Kim S, Kim W, Li X, Jung I, Kim H . Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011; 68(11):1412-20. DOI: 10.1001/archneurol.2011.154. View